October 22, 2014 6:25 PM ET

Pharmaceuticals

Company Overview of Neuraltus Pharmaceuticals, Inc.

Company Overview

Neuraltus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for the treatment of neurodegenerative diseases. Its products include NP001 that regulates macrophage activation for targeting diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis; and NP002, a small molecule and nicotinic receptor agonist to reduce dyskinesias, a primary side effect of L-dopa treatment of Parkinson’s disease. The company’s products also include NP003, an orally bioavailable small molecule to treat lysosomal storage diseases, such as Fabry’s disease and Gaucher’s disease. Neuraltus Pharmaceuticals, Inc. was incorp...

2483 East Bayshore Road

Suite 212

Palo Alto, CA 94303

United States

Founded in 2004

Phone:

650-424-1600

Fax:

650-320-8504

Key Executives for Neuraltus Pharmaceuticals, Inc.

Chief Executive Officer and President
Age: 67
Co-Founder and Chief Operating Officer
Co-Founder
Age: 68
Co-Founder
Compensation as of Fiscal Year 2014.

Neuraltus Pharmaceuticals, Inc. Key Developments

Neuraltus Pharmaceuticals, Inc. Announces Promising Efficacy Results of the Phase 2 Clinical Program of Np001 for the Treatment of Amyotrophic Lateral Sclerosis

Neuraltus Pharmaceuticals, Inc. announced promising efficacy results of the company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) are being highlighted in an oral presentation at the inaugural Summit of the ALS Research Group, being held in Bloomington, Minnesota, September 17-19, 2014. According to a post hoc analysis, administration of a high dose of NP001 (2mg/kg) was associated with a halt in disease progression in 27% of patients, approximately 2.5 times greater than the percentage in patients on placebo (10%). The researchers determined that two major plasma factors -- Interleukin-18 (IL-18) and lipopolysaccharide (LPS), both markers of inflammation -- may differentiate NP001 responders from non-responders. In the analysis, the responder population was shown to have had significantly higher levels of IL-18, a cytokine involved in inflammation-driven cell death, than the non-responders at baseline (p=0.02). Additionally, all NP001 responders had detectable levels of LPS in their plasma, signifying abnormal macrophage function, whereas none of the placebo non-progressors had detectable LPS at baseline. NP001 is a small molecule regulator of inflammatory macrophage activity. Aberrant macrophage activity is believed to be a significant contributor to the pathology underlying ALS. Neuraltus' NP001 is designed to restore the normal functioning of macrophages within the central nervous system. Overall, study efficacy results demonstrated positive trends in the ability of NP001 to slow the rate of disease progression, ranging from 13 to 19% in multiple parameters of clinical benefit, although these pre-defined endpoints did not reach statistical significance. The benefit of NP001 related to the degree of baseline inflammation in patients. Those patients with greater baseline inflammation and who received the high dose of NP001 experienced a 44% greater slope improvement (positive trend did not reach significance, however). Further, NP001 was found to be generally safe and well-tolerated in the study.

Neuraltus Pharmaceuticals Announces Executive Changes

Neuraltus Pharmaceuticals, Inc. announced that Richard L. Casey has been named President and Chief Executive Officer, effective immediately. Mr. Casey brings extensive operational and senior management experience within the biopharma industry, including as the former Chairman and CEO of Scios. He replaces Neuraltus' Interim CEO John Walker. Prior to joining Scios, Mr. Casey was Executive Vice President, Pharmaceuticals, at ALZA Corporation, responsible for all manufacturing, marketing and business development activities at the company.

Neuraltus Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 12:00 PM

Neuraltus Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-09-2013 12:00 PM. Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Similar Private Companies By Industry

Company Name Region
Pure Encapsulations, Inc. United States
AtheroMed, Inc. United States
Channel Therapeutics Inc. United States
K-V Discovery Solutions, Inc. United States
Secretory IgA, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neuraltus Pharmaceuticals, Inc., please visit www.neuraltus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.